Cidara Therapeutics, Inc.
CDTX
$66.34
$2.213.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.72M | -23.48M | -52.31M | -15.99M | -- |
| Total Depreciation and Amortization | 27.00K | 49.00K | 59.00K | 61.00K | -- |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 0.00 | -- |
| Total Other Non-Cash Items | -666.00K | -3.35M | 1.97M | 1.05M | -- |
| Change in Net Operating Assets | -14.60M | 4.83M | 20.87M | -21.82M | -- |
| Cash from Operations | -40.96M | -21.95M | -29.41M | -36.70M | -- |
| Capital Expenditure | -- | -- | 0.00 | -106.00K | -- |
| Sale of Property, Plant, and Equipment | 0.00 | 185.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | 185.00K | 0.00 | -106.00K | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -50.00K | -76.00K | -75.00K | -- |
| Issuance of Common Stock | 383.25M | 127.00K | 98.28M | -- | -- |
| Repurchase of Common Stock | -- | -- | 0.00 | -107.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 137.00K | -- | -- | -- | -- |
| Cash from Financing | 383.39M | 77.00K | 98.21M | -182.00K | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 342.42M | -21.69M | 68.79M | -36.98M | -- |